Long-term visual and anatomic outcome of intravitreal injection of ranibizumab for myopic choroidal neovascularization

Long-term visual and anatomic outcome of intravitreal injection of ranibizumab for myopic choroidal neovascularization - Long-term visual and anatomic outcome of intravitreal injection of ranibizumab for myopic choroidal neovascularization

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020177

Enrollment

Registered

2015-12-14

Start date

2015-12-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myopic choroidal neovascularization

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) high myopia (axial length > 26.5 mm) 2) active CNV at the treatment (the presence of dye leakage on fluorescein angiogram) 3) a long-term follow-up of > 2 years after ranibizumab injection. The patients who participated in the RADIANCE study are also included in the study.

Exclusion criteria

Exclusion criteria: 1) a history of other treatments for myopic CNV (PDT, other anti-VEGF reagents than ranibizumab) 2) a history of vitreoretinal surgery 3) a presence of other ocular complications which could affect the vision (dense cataract, foveal retinal detachment, macular holes, etc.

Design outcomes

Primary

Measure	Time frame
The change of the best collected visual acuity(BCVA) at 2 years after IVR compared to the baseline in patients with myopic CNV.	—

Secondary

Measure	Time frame
1)Absolute BCVA value at 2 years 2)The rate of absence of dye leakage from CNV at 2 years after IVR 3)The number of IVR for 2 years 4)The number of CNV recurrence for 2-year period 5)The CNV size (every 6 months for 2 years) 6)The central retinal thickness (every 6 months for 2 years) 7)The subfoveal choroidal thickness (every 6 months for 2 years) 8)The subfoveal scleral thickness (every 6 months for 2 years) 9)The rate of developing CNV-related chorioretinal atrophy at 2 years after IVR 10)The size of CNV-related chorioretinal atrophy at 2 years after IVR 11)The prognostic factors for the mean change of BCVA at 2 years 12)The prognostic factors for loss of CNV activity (absence of dye leakage) at 2 years 13)The prognostic factors for the size of chorioretinal atrophy at 2 years 14)The patient satisfaction at 2 years compared to the baseline 15)The incidence rate of ocular and systemic adverse events 16)Based on the above data (1-15), we would like to establish the treatment guideline for up to 2 years for myopic CNV.	—

Measure

Time frame

1)Absolute BCVA value at 2 years 2)The rate of absence of dye leakage from CNV at 2 years after IVR 3)The number of IVR for 2 years 4)The number of CNV recurrence for 2-year period 5)The CNV size (every 6 months for 2 years) 6)The central retinal thickness (every 6 months for 2 years) 7)The subfoveal choroidal thickness (every 6 months for 2 years) 8)The subfoveal scleral thickness (every 6 months for 2 years) 9)The rate of developing CNV-related chorioretinal atrophy at 2 years after IVR 10)The size of CNV-related chorioretinal atrophy at 2 years after IVR 11)The prognostic factors for the mean change of BCVA at 2 years 12)The prognostic factors for loss of CNV activity (absence of dye leakage) at 2 years 13)The prognostic factors for the size of chorioretinal atrophy at 2 years 14)The patient satisfaction at 2 years compared to the baseline 15)The incidence rate of ocular and systemic adverse events 16)Based on the above data (1-15), we would like to establish the treatment guideline for up to 2 years for myopic CNV.

—

Countries

Japan

Contacts

Public ContactYuka Onishi

Tokyo Medical and Dental University Ophthalmology

yuka0204@gmail.com03-5803-5302

Outcome results